Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.

Karl GaffneyNicola GullickKirsten MacKayYusuf PatelAlice HeaneyTom SheeranLouise HemmingsPaula Pamies

Published in: Rheumatology advances in practice (2023)

This analysis of real-world data from the UK demonstrates high retention rates for secukinumab over 2 years in patients with PsA or r-axSpA, with a favourable safety profile.

Keyphrases

ankylosing spondylitis
prostate cancer
disease activity
cross sectional
rheumatoid arthritis
electronic health record
big data
radical prostatectomy
systemic lupus erythematosus
machine learning
data analysis